1992
DOI: 10.1016/0163-7258(92)90029-y
|View full text |Cite
|
Sign up to set email alerts
|

Dose-response relationships with antihypertensive drugs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
10
0
1

Year Published

1998
1998
2022
2022

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(12 citation statements)
references
References 213 publications
1
10
0
1
Order By: Relevance
“…Our data agree with previous studies demonstrating the unpredictable response of intravenous hydralazine that may be associated with highly variable pharmacodynamics (79). We did identify certain clinical factors that predicted a greater response to intravenous hydralazine including history of arrhythmia and concurrent use of blockers of the renin-angiotensin system.…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…Our data agree with previous studies demonstrating the unpredictable response of intravenous hydralazine that may be associated with highly variable pharmacodynamics (79). We did identify certain clinical factors that predicted a greater response to intravenous hydralazine including history of arrhythmia and concurrent use of blockers of the renin-angiotensin system.…”
Section: Discussionsupporting
confidence: 93%
“…Intravenous hydralazine, is a potent vasodilator with a rapid onset of action that has an unpredictable effect on BP and unpredictable dose response (79). The approved indication for intravenous hydralazine is the management of severe hypertension when medication cannot be given orally and when there is need to urgently reduce blood pressure (10).…”
Section: Introductionmentioning
confidence: 99%
“…12 Unfortunately, failure to properly define the lower end of the dose-response relationship and hence, the lowest effective dose, has been responsible for the introduction of many antihypertensive drugs into clinical practice at excessively high doses. Because efficacy data are often incomplete due to failure to adequately explore the lower or upper extreme of the dose, E max analysis of receptor-blocking drugs has only occasionally been used in phase II and phase III clinical trials.…”
mentioning
confidence: 99%
“…1 Esse fármaco pode causar efeitos colaterais maternos em função do seu efeito farmacológico incluindo taquicardia, cefaleia, hipotensão, náusea, palpitação, tonteira e retenção de sal (A,B). 19,20 A nifedipina é bloqueador dos canais de cálcio tipo 2. Essa ação leva primariamente ao relaxamento do músculo liso, atuando principalmente sobre a musculatura vascular, uterina e vesical.…”
Section: Resultsunclassified